Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. (“JinSai Pharmaceutical”), has received written notification from the U.S. Food and Drug Administration (“FDA”) that the clinical trial application for the injection GenSci143 has been accepted, targeting the indication of advanced solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.